Zongertinib for HER2-positive cancers that have spread
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be HER2-positive and have spread to other parts of the body (metastatic).
- You must have already received at least one prior treatment for advanced cancer, and your cancer has progressed (grown) despite that treatment.
- You must have at least one tumor that can be measured on scans.
- You must be in good enough physical condition to be up and active (ECOG score 0 or 1).
- You cannot have untreated or worsening brain metastases or a history of certain heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This trial tests whether a targeted drug (zanidatamab, which attacks HER2-positive cancer cells) combined with chemotherapy can shrink stomach cancer before surgery, making it easier to remove. It may also help people whose cancer has spread a bit, by making it operable.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This trial tests an experimental pill called zongertinib for people with different types of advanced solid tumors that have a specific genetic change called HER2. It's a treatment option when other therapies haven't worked, and it may help shrink or slow the cancer.
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
This study tests a new pill (zongertinib) combined with fulvestrant (an injection) for people with advanced breast cancer that has a HER2 mutation. The combination may help stop or slow the cancer growth.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.